Publicaciones en colaboración con investigadores/as de Hospital Universitario Central de Asturias (16)

2020

  1. Seroprevalence and epidemiology of hepatitis B and C viruses in pregnant women in Spain. Risk factors for vertical transmission

    PLoS ONE, Vol. 15, Núm. 5

2019

  1. Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain

    PLoS ONE, Vol. 14, Núm. 11

2017

  1. Interferon-related genetic markers of necroinflammatory activity in chronic hepatitis C

    PLoS ONE, Vol. 12, Núm. 7

  2. Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study

    World Journal of Gastroenterology, Vol. 23, Núm. 41, pp. 7459-7469

2015

  1. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis

    World Journal of Gastroenterology, Vol. 21, Núm. 30, pp. 9163-9174

  2. Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection

    Genes and Immunity, Vol. 16, Núm. 5, pp. 297-300

2013

  1. Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy

    Genes and Immunity, Vol. 14, Núm. 5, pp. 317-324

2011

  1. Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C

    Clinical Pharmacology and Therapeutics, Vol. 90, Núm. 5, pp. 712-721

2008

  1. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C

    Journal of Hepatology, Vol. 48, Núm. 5, pp. 721-727

  2. Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C

    Hepatology, Vol. 47, Núm. 3, pp. 810-816

2007

  1. Induction doses of interferon-α-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: A randomized trial

    Journal of Viral Hepatitis, Vol. 14, Núm. 2, pp. 89-95

  2. Treatment of chronic he1patitis C genotype 1 with peginterferon- α2a (40 kDa) plus ribavirin under routine clinical practice in Spain: Early prediction of sustained virological response rate

    Alimentary Pharmacology and Therapeutics, Vol. 25, Núm. 8, pp. 899-906

2005

  1. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period

    Gastroenterology, Vol. 129, Núm. 2, pp. 512-521

2004

  1. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease

    Hepatology, Vol. 39, Núm. 6, pp. 1603-1612

2003

  1. Comparative study of the efficacy of an induction dose of interferon-α2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C

    Journal of Viral Hepatitis, Vol. 10, Núm. 6, pp. 437-445

2000

  1. Trovafloxacin-induced acute hepatitis

    Clinical Infectious Diseases, Vol. 30, Núm. 2, pp. 400-401